TP53 and non-small cell lung carcinoma: As far as we know, this is the first study to investigate the predictive role of genomic alternations through the ctDNA detection in HER2 mutant NSCLC, and we found that TP53 mutation was associated with the inferior efficacy of pyrotinib.